These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1710317)

  • 41. Effects of cyclolinopeptide A on T lymphocyte activation and peptidyl prolyl isomerase activity.
    Gaymes TJ; Carrett NJ; Patel N; Kay JE; Siemion IZ
    Biochem Soc Trans; 1996 Feb; 24(1):90S. PubMed ID: 8674774
    [No Abstract]   [Full Text] [Related]  

  • 42. Catalysis steps.
    Stein RL
    Nature; 1992 Mar; 356(6364):23-4. PubMed ID: 1538777
    [No Abstract]   [Full Text] [Related]  

  • 43. Mechanism of enzymatic and nonenzymatic prolyl cis-trans isomerization.
    Stein RL
    Adv Protein Chem; 1993; 44():1-24. PubMed ID: 8317295
    [No Abstract]   [Full Text] [Related]  

  • 44. Structural studies of complexed FK-506 binding protein.
    Clardy J
    Ann N Y Acad Sci; 1993 Jun; 685():37-45. PubMed ID: 7689808
    [No Abstract]   [Full Text] [Related]  

  • 45. Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy.
    Kallen J; Spitzfaden C; Zurini MG; Wider G; Widmer H; Wüthrich K; Walkinshaw MD
    Nature; 1991 Sep; 353(6341):276-9. PubMed ID: 1896075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization.
    Zhao Y; Ke H
    Biochemistry; 1996 Jun; 35(23):7356-61. PubMed ID: 8652511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structure-based design of novel, urea-containing FKBP12 inhibitors.
    Dragovich PS; Barker JE; French J; Imbacuan M; Kalish VJ; Kissinger CR; Knighton DR; Lewis CT; Moomaw EW; Parge HE; Pelletier LA; Prins TJ; Showalter RE; Tatlock JH; Tucker KD; Villafranca JE
    J Med Chem; 1996 Apr; 39(9):1872-84. PubMed ID: 8627611
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FK506 as an agonist to induce inhibition of interleukin 2 production.
    Bundick RV; Donald DK; Eady RP; Hutchinson R; Keogh RW; Schmidt JA; Wells E
    Transplantation; 1992 May; 53(5):1150-3. PubMed ID: 1374947
    [No Abstract]   [Full Text] [Related]  

  • 49. A natural specific intracellular ligand as a reagent for cyclosporine blood level determination.
    Hasková V; Rozprimová L; Svobodová J
    Folia Biol (Praha); 1991; 37(2):134-9. PubMed ID: 1874341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate.
    Rosen MK; Standaert RF; Galat A; Nakatsuka M; Schreiber SL
    Science; 1990 May; 248(4957):863-6. PubMed ID: 1693013
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New trends in immunosuppression for renal transplantation.
    Halloran PF
    Curr Opin Nephrol Hypertens; 1994 Nov; 3(6):575-7. PubMed ID: 7881978
    [No Abstract]   [Full Text] [Related]  

  • 52. Rusting of the lock and key model for protein-ligand binding.
    Jorgensen WL
    Science; 1991 Nov; 254(5034):954-5. PubMed ID: 1719636
    [No Abstract]   [Full Text] [Related]  

  • 53. Human immunodeficiency virus. Chaperoning a pathogen.
    Cullen BR; Heitman J
    Nature; 1994 Nov; 372(6504):319-20. PubMed ID: 7526224
    [No Abstract]   [Full Text] [Related]  

  • 54. The mechanism of action of cyclosporine: a perspective for the 90's.
    Halloran PF; Madrenas J
    Clin Biochem; 1991 Feb; 24(1):3-7. PubMed ID: 1711939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo pharmacological effects of ciclosporin and some analogues.
    Borel JF; Baumann G; Chapman I; Donatsch P; Fahr A; Mueller EA; Vigouret JM
    Adv Pharmacol; 1996; 35():115-246. PubMed ID: 8920206
    [No Abstract]   [Full Text] [Related]  

  • 56. Fault lines in the HIV core?
    Nat Struct Biol; 1997 Feb; 4(2):85-6. PubMed ID: 9033580
    [No Abstract]   [Full Text] [Related]  

  • 57. Simulations of enzymic reactions.
    Mulholland AJ; Karplus M
    Biochem Soc Trans; 1996 Feb; 24(1):247-54. PubMed ID: 8674677
    [No Abstract]   [Full Text] [Related]  

  • 58. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin.
    Griffiths EJ; Halestrap AP
    Biochem J; 1991 Mar; 274 ( Pt 2)(Pt 2):611-4. PubMed ID: 1706598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interspecies comparison of the immunosuppressive efficacy and safety of FK 506.
    Thomson AW
    Transplant Proc; 1990 Feb; 22(1):100-5. PubMed ID: 1689883
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunosuppressive properties of cyclosporin metabolites.
    Küllinger B; Steiner G; Woloszczuk W
    Lancet; 1989 Aug; 2(8658):333-4. PubMed ID: 2569136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.